Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Age related macular degeneration)
40,122 results
  • Ocular health screening among care-center residents with disabilities: a smartphone adaptive fundus camera cross-sectional study. [Journal Article]
    Eur Rev Med Pharmacol Sci. 2023 Jan; 27(2):620-627.Ay IE, Kose F
  • CONCLUSIONS: Screening for ocular health with a novel smartphone-adapted fundus camera revealed significantly higher rates of various ocular diseases in care center disabled residents. Given technological progress, remote control method-assisted ocular exams appear to be potentially feasible and clinically beneficial. This could allow trained allied health personnel to perform ocular health screenings without the need to transport a disabled person to the hospital. Thus, diagnosis and follow-up of various chronic ocular diseases may be properly organized.
  • Effects of Systemic Drugs on the Development and Progression of Age-Related Macular Degeneration. [Review]
    Surv Ophthalmol. 2023 Jan 30 [Online ahead of print]Grimes KR, Aloney A, … Chhablani J
  • Age-related macular degeneration (AMD) is the leading cause of severe loss of central vision among people over 50. The pathophysiology of the disease is multifactorial and can be attributed to genetics, aging, inflammation, environmental factors, and lifestyle factors including smoking, diet, obesity, and alcohol consumption. While there is no treatment for dry AMD, the current standard treatment…
  • Effect of dexamethasone implant on intraocular cytokines in diabetic macular edema. [Journal Article]
    Indian J Ophthalmol. 2023 Feb; 71(2):363-368.Pillai GS, Gupta A, … Ravindran GC
  • CONCLUSIONS: Our study suggests that dexamethasone acts more on IC than VEGF in DME. This is significant in the first 3 months with a rebound effect on IL-6 after 3 months. Our study also suggests that repeat injection of DEX in DME should be done at 3 months to prevent deterioration of visual acuity (VA) and worsening of CMT.
  • Prevalence of visual impairment in older people living with dementia and its impact: a scoping review. [Review]
    BMC Geriatr. 2023 Feb 01; 23(1):63.Zhang W, Roberts TV, … Stanaway FF
  • CONCLUSIONS: VI is common in older people living with dementia and is associated with negative impacts on those with dementia and their caregivers. However, heterogeneity between studies in terms of setting and method for assessing and defining VI make it difficult to compare findings among studies. Further research is needed, particularly assessing the impact on caregivers.
  • PRMT5 is a therapeutic target in choroidal neovascularization. [Journal Article]
    Sci Rep. 2023 Jan 31; 13(1):1747.Muniyandi A, Martin M, … Corson TW
  • Ocular neovascular diseases including neovascular age-related macular degeneration (nvAMD) are widespread causes of blindness. Patients' non-responsiveness to currently used biologics that target vascular endothelial growth factor (VEGF) poses an unmet need for novel therapies. Here, we identify protein arginine methyltransferase 5 (PRMT5) as a novel therapeutic target for nvAMD. PRMT5 is a well-…
New Search Next